Recon: FDA panel votes against Otsuka, Lundbeck PTSD drug; Biogen announces $2B upgrades to NC facilities
ReconJason Scott
Biologics/ biosimilars/ vaccinesEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicyUnited States